{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:17:10Z","timestamp":1784557030933,"version":"3.55.0"},"reference-count":12,"publisher":"Bioscientifica","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["edm.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>A Caucasian man in his 60s with recent diagnosis of metastatic renal cell carcinoma presented to the emergency department with a 5-day history of severe polyuria, polydipsia and fatigue and 1-day history of confusion, abdominal pain, nausea and vomiting. Investigations revealed an overlap of diabetic ketoacidosis (DKA) and hyperosmolar hyperglycaemic state (HHS). He had received the first dose of immunotherapy with nivolumab and ipilimumab 3 weeks prior to this attendance. New-onset type 1 diabetes (T1DM) was confirmed based on the clinical features at presentation, seropositivity for glutamic acid decarboxylase antibodies and significant insulin deficiency. He is currently on a multiple daily injections of insulin and uses intermittent-scanned glucose monitoring. Given the irreversible impact on beta-cell function and clinical response with insulin resulting in improved diabetes control, immunotherapy was resumed for his metastatic cancer with good radiological response. Although rare, new-onset T1DM can present with DKA and HSS overlap after a single dose of nivolumab\/ipilimumab in individuals without pre-existing history of diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Learning points<\/jats:title>\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>Although rare, new onset of T1DM after immunotherapy can present with DKA and HSS overlap after a single dose of nivolumab\/ipilimumab in individuals without pre-existing history of diabetes and normal glycaemic parameters.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Due to the irreversible destruction of beta-cells, treatment with steroids is not indicated in contrast to other settings such as immunotherapy-induced hypophysitis.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Presence of low c-peptide levels post-acute presentation is indicative of an irreversible impact on beta-cell function and supports resuming immunotherapy given the significant benefits on cancer prognosis.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Clinicians must maintain a high index of suspicion in regards to diagnosis and management of new-onset type 1 diabetes and advice patients on reporting symptoms suggestive of diabetes and\/or diabetes-related hyperglycaemic emergencies.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:sec>","DOI":"10.1530\/edm-22-0389","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T07:33:40Z","timestamp":1692171220000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-2","source":"Crossref","is-referenced-by-count":2,"title":["Presentation of new onset type 1 diabetes with diabetic ketoacidosis and hyperosmolar hyperglycaemia after a single dose of nivolumab and ipilimumab"],"prefix":"10.1530","volume":"2023","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7753-8592","authenticated-orcid":true,"given":"Dimitra","family":"Stathi","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes, Guy\u2019s and St Thomas\u2019 NHS Trust, London, UK"},{"name":"School of Cardiovascular Medicine & Sciences, King's College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sufyan","family":"Hussain","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Guy\u2019s and St Thomas\u2019 NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Crawley","sequence":"additional","affiliation":[{"name":"Department of Oncology, Guy\u2019s and St Thomas\u2019 NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janaka","family":"Karalliedde","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Guy\u2019s and St Thomas\u2019 NHS Trust, London, UK"},{"name":"School of Cardiovascular Medicine & Sciences, King's College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"International Journal of Molecular Sciences","first-page":"4427","article-title":"Combination of ipilimumab and nivolumab in cancers: from clinical practice to ongoing clinical trials","volume":"21","author":"Kooshkaki","year":"2020","unstructured":"Kooshkaki ODerakhshani AHosseinkhani NTorabi MSafaei SBrunetti ORacanelli VSilvestris N & Baradaran B. Combination of ipilimumab and nivolumab in cancers: from clinical practice to ongoing clinical trials. International Journal of Molecular Sciences2020214427. (https:\/\/doi.org\/10.3390\/ijms21124427)"},{"key":"bib2","series-title":"Journal of Clinical Medicine","first-page":"2033","article-title":"Endocrinopathies associated with immune checkpoint inhibitor cancer treatment: a review","volume":"9","author":"Okura","year":"2020","unstructured":"Okura NAsano MUchino JMorimoto YIwasaku MKaneko YYamada TFukui M & Takayama K. Endocrinopathies associated with immune checkpoint inhibitor cancer treatment: a review. Journal of Clinical Medicine202092033. (https:\/\/doi.org\/10.3390\/jcm9072033)"},{"key":"bib3","series-title":"Annals of Pediatric Endocrinology and Metabolism","first-page":"69","article-title":"Hyperosmolar hyperglycemic state as the first manifestation of type 1 diabetes mellitus in an adolescent male: a case report","volume":"27","author":"Chun","year":"2022","unstructured":"Chun SHLee HS & Hwang JS. Hyperosmolar hyperglycemic state as the first manifestation of type 1 diabetes mellitus in an adolescent male: a case report. Annals of Pediatric Endocrinology and Metabolism20222769\u201372. (https:\/\/doi.org\/10.6065\/apem.2142002.001)"},{"key":"bib4","series-title":"Nature Reviews. Endocrinology","first-page":"389","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","unstructured":"Wright JJPowers AC & Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nature Reviews. Endocrinology202117389\u2013399. (https:\/\/doi.org\/10.1038\/s41574-021-00484-3)"},{"key":"bib5","series-title":"Clinical Diabetes","first-page":"10","article-title":"Standards of medical care in Diabetes-2022 abridged for primary care providers","volume":"40","year":"2022","unstructured":"American Diabetes Association. Standards of medical care in Diabetes-2022 abridged for primary care providers. Clinical Diabetes20224010\u201338. (https:\/\/doi.org\/10.2337\/cd22-as01)"},{"key":"bib6","series-title":"Typ","year":"2017","unstructured":"National Institute for Health and Care Excellence. Type 2 Diabetes: Prevention in People at High Risk [PH38]. 2017. (www.nice.org.uk\/guidance\/ph38)"},{"key":"bib7","series-title":"Journal of Experimental Medicine","first-page":"63","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice","volume":"198","author":"Ansari","year":"2003","unstructured":"Ansari MJSalama ADChitnis TSmith RNYagita HAkiba HYamazaki TAzuma MIwai HKhoury SJ, The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. Journal of Experimental Medicine200319863\u201369. (https:\/\/doi.org\/10.1084\/jem.20022125)"},{"key":"bib8","series-title":"European Journal of Endocrinology","first-page":"363","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette","year":"2019","unstructured":"de Filette JMKPen JJDecoster LVissers TBravenboer BVan der Auwera BJGorus FKRoep BOAspeslagh SNeyns B, Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. European Journal of Endocrinology2019181363\u2013374. (https:\/\/doi.org\/10.1530\/EJE-19-0291)"},{"key":"bib9","series-title":"BMJ Case Reports","article-title":"New onset diabetes after nivolumab treatment","author":"Capitao","year":"2018","unstructured":"Capitao RBello CFonseca R & Saraiva C. New onset diabetes after nivolumab treatment. BMJ Case Reports2018. (https:\/\/doi.org\/10.1136\/bcr-2017-220999)"},{"key":"bib10","series-title":"European Journal of Case Reports in Internal Medicine","first-page":"002756","article-title":"Hyperosmolar Hyperglycaemic State and diabetic ketoacidosis in nivolumab-induced insulin-dependent diabetes mellitus","volume":"8","author":"Saleh","year":"2021","unstructured":"Saleh AOTaha RMohamed SFA & Bashir M. Hyperosmolar Hyperglycaemic State and diabetic ketoacidosis in nivolumab-induced insulin-dependent diabetes mellitus. European Journal of Case Reports in Internal Medicine20218002756. (https:\/\/doi.org\/10.12890\/2021_002756)"},{"key":"bib11","series-title":"Journal for ImmunoTherapy of Cancer","first-page":"40","article-title":"Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer","volume":"5","author":"Godwin","year":"2017","unstructured":"Godwin JLJaggi SSirisena ISharda PRao ADMehra R & Veloski C. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. Journal for ImmunoTherapy of Cancer2017540. (https:\/\/doi.org\/10.1186\/s40425-017-0245-2)"},{"key":"bib12","series-title":"New England Journal of Medicine","first-page":"603","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for Type 1 diabetes","volume":"381","author":"Herold","year":"2019","unstructured":"Herold KCBundy BNLong SABluestone JADiMeglio LADufort MJGitelman SEGottlieb PAKrischer JPLinsley PS, An anti-CD3 antibody, teplizumab, in relatives at risk for Type 1 diabetes. New England Journal of Medicine2019381603\u2013613. (https:\/\/doi.org\/10.1056\/NEJMoa1902226)"}],"container-title":["Endocrinology, Diabetes &amp; Metabolism Case Reports"],"original-title":[],"link":[{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2023\/3\/EDM22-0389.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2023\/3\/EDM22-0389.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2023\/3\/EDM22-0389.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:48:07Z","timestamp":1784555287000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/edm\/article\/3556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":12,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1530\/edm-22-0389","relation":{},"ISSN":["2052-0573"],"issn-type":[{"value":"2052-0573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}